22/05/2013
|
CIS nations' drug reimbursement plans "could completely change their markets"
Russia, Ukraine and Kazakhstan have recently taken steps to introduce drug reimbursement schemes which, if introduced, could completely change the operating environment for both their innovative drug and generic markets, says new research.
At present, the rate of growth for innovative medicines in these Commonwealth of Independent States (CIS) nations is lower than for generics; last...
Read more... 
|
|
: |
22/05/2013
|
Kidney function drop similar with/without HIV in study of US women
Estimated glomerular filtration rate (eGFR) declined at a similar annual pace in antiretroviral-treated women with HIV and women without HIV in the US Women’s Interagency HIV Study (WIHS). But HIV-positive women had significantly lower average eGFRs at follow-up than did HIV-negative women.
Research suggests that HIV infection accelerates kidney function decline, but few...
Read more...
|
|
|
22/05/2013
|
Facial fat atrophy in 54% of ART- treated patients in French study
Facial lipoatrophy affected more than half of HIV-positive French patients taking antiretroviral therapy (ART) for at least 1 year in large study. Although longer time on ART raised chances of facial lipoatrophy, more than a quarter of study participants treated 1 to 5 years had lipoatrophy.
French investigators planned this multicenter, cross-sectional study to assess prevalence...
Read more...
|
|
|
22/05/2013
|
Another step toward eliminating HIV infection?
In two patients, allogeneic stem-cell transplantation under the cover of ART produced sustained reduction of HIV reservoirs in peripheral blood mononuclear cells.
The challenges of lifelong antiretroviral therapy (ART) led to the prioritization of research toward eradication of HIV infection or interventions that could result in a drug-free remission. This effort was catalyzed by...
Read more...
|
|
|
22/05/2013
|
European Medicines Agency validates Gilead’s Marketing Application for sofosbuvir for the treatment of hepatitis C
Once-daily sofosbuvir will receive an accelerated assessment by EMA
Designation granted to new medicines of major public health interest
FOSTER CITY, Calif.--(BUSINESS WIRE)--May. 21, 2013-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Marketing Authorisation Application (MAA) for sofosbuvir, a once-daily oral nucleotide analogue inhibitor...
Read more...
|
|
